Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Oct;38(10):2340–2345. doi: 10.1128/aac.38.10.2340

Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections.

H Wakebe 1, T Imada 1, H Yoneda 1, F Mukai 1, K Ohguro 1, K Ohmori 1, H Tamaoka 1, Y Yabuuchi 1
PMCID: PMC284741  PMID: 7840567

Abstract

The antibacterial activity of OPC-17116, a new fluoroquinolone antibacterial agent, against important pathogens that cause respiratory tract infections was evaluated in vitro and in vivo and compared with those of ciprofloxacin, ofloxacin, and norfloxacin. The pharmacokinetic profiles of OPC-17116 were studied in both mice and rats given the drug orally at doses of 50 and 40 mg/kg of body weight, respectively. OPC-17116 showed a high degree of distribution in the lung tissues of both species, with maximum concentrations of 29.6 and 32.0 micrograms/g, respectively. Furthermore, the drug concentrations in lung tissue were about 10 to 15 times greater than the concentrations in plasma. OPC-17116 showed potent antibacterial activity against such pathogens as Staphylococcus aureus, Streptococcus pneumoniae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, and Moraxella catarrhalis. The MICs of this compound for 90% of these organisms except methicillin-resistant S. aureus and P. aeruginosa ranged from < or = 0.006 to 0.78 microgram/ml. The in vitro antibacterial activity of OPC-17116 was reflected by the efficacy of a single oral dose against systemic bacterial infections in mice. OPC-17116 showed a superior effect against gram-positive bacteria, H. influenzae, and M. catarrhalis. In comparison with the other reference compounds, the efficacy of OPC-17116 was less than that of ciprofloxacin against K. pneumoniae and P. aeruginosa. OPC-17116 showed a greater therapeutic effect than the other drugs against experimental acute pneumonia caused by these organisms in mice or rats. This excellent therapeutic effect against respiratory tract infections may be a result of its high level of distribution in lung tissue.

Full text

PDF
2340

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Doern G. V., Tubert T. A. In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods. Antimicrob Agents Chemother. 1988 Feb;32(2):259–261. doi: 10.1128/aac.32.2.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gotoh N., Tanaka S., Nishino T. Supersusceptibility to hydrophobic antimicrobial agents and cell surface hydrophobicity in Branhamella catarrhalis. FEMS Microbiol Lett. 1989 May;50(1-2):211–213. doi: 10.1016/0378-1097(89)90488-6. [DOI] [PubMed] [Google Scholar]
  3. HAIGHT T. H., FINLAND M. Observations on mode of action of erythromycin. Proc Soc Exp Biol Med. 1952 Oct;81(1):188–193. doi: 10.3181/00379727-81-19817. [DOI] [PubMed] [Google Scholar]
  4. Imada T., Miyazaki S., Nishida M., Yamaguchi K., Goto S. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrob Agents Chemother. 1992 Mar;36(3):573–579. doi: 10.1128/aac.36.3.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kobayashi Y., Kanazawa K., Nishino T. Transmembrane diffusion of hydrophobic antimicrobial agents and cell surface hydrophobicity in Bacteroides fragilis. FEMS Microbiol Lett. 1991 Jun 15;65(2):141–144. doi: 10.1016/0378-1097(91)90293-j. [DOI] [PubMed] [Google Scholar]
  6. Muto Y., Bandoh K., Watanabe K., Katoh N., Ueno K. Macrolide accumulation by Bacteroides fragilis ATCC 25285. Antimicrob Agents Chemother. 1989 Feb;33(2):242–244. doi: 10.1128/aac.33.2.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Neu H. C., Fang W., Gu J. W., Chin N. X. In vitro activity of OPC-17116. Antimicrob Agents Chemother. 1992 Jun;36(6):1310–1315. doi: 10.1128/aac.36.6.1310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Nikaido H., Vaara M. Molecular basis of bacterial outer membrane permeability. Microbiol Rev. 1985 Mar;49(1):1–32. doi: 10.1128/mr.49.1.1-32.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Nishi T., Tsuchiya K. Experimental respiratory tract infection with Klebsiella pneumoniae DT-S in mice: chemotherapy with kanamycin. Antimicrob Agents Chemother. 1980 Mar;17(3):494–505. doi: 10.1128/aac.17.3.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ridgway G. L. A review of the in-vitro activity of roxithromycin against genital pathogens. J Antimicrob Chemother. 1987 Nov;20 (Suppl B):7–11. doi: 10.1093/jac/20.suppl_b.7. [DOI] [PubMed] [Google Scholar]
  11. Wakebe H., Mitsuhashi S. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria. Antimicrob Agents Chemother. 1992 Oct;36(10):2185–2191. doi: 10.1128/aac.36.10.2185. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES